Cargando…

BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition

Detalles Bibliográficos
Autores principales:	Meng, Yu, Sun, Hui-Yan, He, Yi, Zhou, Qian, Liu, Yi-Huang, Su, Hui, Yin, Ming-Zhu, Zeng, Fu-Rong, Chen, Xiang, Deng, Guang-Tong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694977/ https://www.ncbi.nlm.nih.gov/pubmed/38049916 http://dx.doi.org/10.1186/s40779-023-00497-1

Ejemplares similares

BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression
por: Zeng, Furong, et al.
Publicado: (2023)

EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma
por: Deng, Guangtong, et al.
Publicado: (2022)

BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway
por: Deng, Guangtong, et al.
Publicado: (2020)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy
por: Ascierto, Maria Libera, et al.
Publicado: (2015)

Ferroptosis-related gene AKR1C1 predicts the prognosis of non-small cell lung cancer
por: Huang, Fangfang, et al.
Publicado: (2021)

Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma
por: Xu, Yujian, et al.
Publicado: (2022)

Inhibiting SCD expression by IGF1R during lorlatinib therapy sensitizes melanoma to ferroptosis
por: Zeng, Furong, et al.
Publicado: (2023)

Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma
por: Wang, Shengmei, et al.
Publicado: (2023)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Multi-omics characterization and therapeutic liability of ferroptosis in melanoma
por: He, Yi, et al.
Publicado: (2022)

Role of ferroptosis in esophageal cancer and corresponding immunotherapy
por: Fan, Xin, et al.
Publicado: (2023)

AKR1C1 Protects Corneal Epithelial Cells Against Oxidative Stress-Mediated Ferroptosis in Dry Eye
por: Zuo, Xin, et al.
Publicado: (2022)

Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate
por: Khanim, F, et al.
Publicado: (2014)

The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
por: Zhao, Bei, et al.
Publicado: (2018)

Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
por: Echevarría‐Vargas, Ileabett M, et al.
Publicado: (2018)

AKR1B10 in gastrointestinal diseases
por: Shen, Yi, et al.
Publicado: (2015)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases
por: Rižner, Tea Lanišnik
Publicado: (2012)

In-silico Investigations of quinine and quinidine as potential Inhibitors of AKR1B1 and AKR1B10: Functional and structural characterization
por: Ejaz, Syeda Abida, et al.
Publicado: (2022)

Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis
por: Verma, Nandini, et al.
Publicado: (2020)

A Ferroptosis-Related Gene Signature for Predicting Survival and Immunotherapy Effect in Renal Cancer
por: Tong, Liang, et al.
Publicado: (2022)

Ferroptosis: a new approach for immunotherapy
por: Zeng, Chong, et al.
Publicado: (2020)

Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism for cancer immunotherapy
por: Du, Songtao, et al.
Publicado: (2023)

Analogues of Natural Chalcones as Efficient Inhibitors of AKR1C3
por: Möller, Gabriele, et al.
Publicado: (2022)

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
por: Heinemann, Anja, et al.
Publicado: (2015)

A Novel Acetylation-Immune Subtyping for the Identification of a BET Inhibitor-Sensitive Subgroup in Melanoma
por: Wang, Liuying, et al.
Publicado: (2023)

Liquiritin, as a Natural Inhibitor of AKR1C1, Could Interfere With the Progesterone Metabolism
por: Zeng, Chenming, et al.
Publicado: (2019)

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling
por: Dai, Zhiyu, et al.
Publicado: (2019)

Ferroptosis-Related Gene Signature Predicts the Prognosis of Skin Cutaneous Melanoma and Response to Immunotherapy
por: Xu, Ziqian, et al.
Publicado: (2021)

Targeting Wnt/β-Catenin Signaling Exacerbates Ferroptosis and Increases the Efficacy of Melanoma Immunotherapy via the Regulation of MITF
por: Wang, Hao, et al.
Publicado: (2022)

Up-Regulated AKR1C2 is correlated with favorable prognosis in thyroid carcinoma
por: Jin, Yi-Xiang, et al.
Publicado: (2019)

Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma: The role of Arginase 2 in sorafenib-induced ferroptosis in melanoma
por: Yu, Yi, et al.
Publicado: (2022)

Aldo–Keto Reductase AKR1C1–AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy
por: Zeng, Chen-Ming, et al.
Publicado: (2017)

Design and Characterization of Bivalent BET Inhibitors
por: Tanaka, Minoru, et al.
Publicado: (2016)

Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers
por: Laffin, Brian, et al.
Publicado: (2012)

Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma
por: Zhu, Pengfei, et al.
Publicado: (2021)

AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas
por: Hojnik, Marko, et al.
Publicado: (2021)

Ferroptosis-Associated Classifier and Indicator for Prognostic Prediction in Cutaneous Melanoma
por: Zeng, Hao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lqnnh2ps7652e0okjiejd4lo6u